Showing results (271-280 of 319) with videos related to

Sort By:
Pageof 32
Lancet (London, England)|January 10, 2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trialYung-Jue Bang, Young-Woo Kim, Han-Kwang Yang, et al.
BMC Cancer|February 9, 2018
Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcomaYong Jin Cho, Soo Hee Kim, Eun Kyung Kim, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 27, 2019
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 studyYung-Jue Bang, Yoon-Koo Kang, Daniel V Catenacci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2007
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatmentEva S Thomas, Henry L Gomez, Rubi K Li, et al.
Journal for Immunotherapy of Cancer|February 6, 2019
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trialHyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2021
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10Zev A Wainberg, Charles S Fuchs, Josep Tabernero, et al.
BMC Cancer|July 10, 2016
Prognostic implications of PD-L1 expression in patients with soft tissue sarcomaChan Kim, Eun Kyung Kim, Hun Jung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2013
Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 studyAtsushi Ohtsu, Jaffer A Ajani, Yu-Xian Bai, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|October 31, 2023
Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II studyChoong-Kun Lee, Jii Bum Lee, Se Jung Park, et al.
Annals of Surgical Oncology|July 28, 2018
Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC TrialHyung Soon Park, Hyo Song Kim, Seung Hoon Beom, et al.
Pageof 32